Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect, HydraSpace, and select toxSYN linker-payloads
Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized therapeutic index
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin ), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, and Synaffix B.V. (CEO: Peter van de Sande, Synaffix ), a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug conjugates (ADCs), today announced the signing of a license and option agreement.
Setback for Kyowa s Nouryant in Parkinson s disease treatment in Europe
pharmaceutical-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-technology.com Daily Mail and Mail on Sunday newspapers.
Japanese Market Modestly Higher
TOKYO (dpa-AFX) - The Japanese stock market is modestly higher on Tuesday, extending the gains of the previous two sessions, with the benchmark Nikkei index breaking above the 28,000 mark, following the positive cues from Wall Street overnight, ignoring the surge in the coronavirus s delta variant infections amid the ongoing Tokyo Olympics.
The benchmark Nikkei 225 Index is gaining 173.11 points or 0.62 percent to 28,006.40, after touching a high of 28,036.23 earlier. Japanese shares closed significantly higher on Monday.
Market heavyweight SoftBank Group is edging down 0.2 percent, while Uniqlo operator Fast Retailing is gaining almost 1 percent. Among automakers, Honda and Toyota are gaining almost 1 percent each.
Asian Markets Mostly Higher
CANBERA (dpa-AFX) - Asian stock markets are trading mostly higher on Tuesday, following the positive cues from Wall Street overnight, as upbeat earnings news contributed to rebound along with continued optimism about the economy, despite some concerns about the spread of new coronavirus variants. Investors also await the U.S. Federal Reserve s monetary policy announcement on Wednesday for clues on the timing of stimulus tapering and the outlook for the global economy. Asian stocks ended mostly lower Monday.
The Australian stock market is modestly higher on Tuesday, after the slight losses of the previous session, with the benchmark S&P/ASX 200 breaking above the 7,400 level to fresh all-time highs, following the positive cues from Wall Street overnight, with materials and energy stocks lifting the market. Traders remain concerned about the spread of the highly contagious coronavirus variants in more states.
Kyowa Kirin gibt EU-Zulassung für die Selbstverabreichung von CRYSVITA® ▼ (Burosumab) zur Behandlung der X-chromosomalen Hypophosphatämie (XLH) bekannt 20 Jul 2021
Kyowa Kirin Co. Ltd. (TSE: 4151, Kyowa Kirin) gab heute bekannt, dass CRYSVITA
® (Burosumab) die EU-Zulassung zur Behandlung der X-chromosomalen Hypophosphatämie (XLH), einer seltenen Knochenstoffwechselerkrankung, an der Kinder und Erwachsene erkranken können, für die Selbstverabreichung erhalten hat. Die Zulassung bedeutet, dass bestimmte Patienten oder Pflegepersonen gegebenenfalls dafür geeignet sind, CRYSVITA auf Empfehlung des behandelnden Arztes selbst zu verabreichen, und zwar bei der zugelassenen Indikation zur Behandlung von XLH bei Kindern und Jugendlichen im Alter von 1 bis 17 Jahren mit röntgenologischem Nachweis einer Knochenerkrankung sowie bei Erwachsenen.
vimarsana © 2020. All Rights Reserved.